Micah Steffek

机构：Tetra Therapeutics (United States) · ORCID：0000-0002-8253-4983

发表论文 43 篇 · 总被引 2208 次 · h-index 24

代表论文

• An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance (2023 · Nature Cancer · 被引 206)
• Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab (2020 · Science · 被引 201)
• Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling (2020 · Cell Reports · 被引 176)
• Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization (2020 · Nature Structural & Molecular Biology · 被引 103)
• Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes (2024 · Cell · 被引 88)
• Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design (2013 · Bioorganic & Medicinal Chemistry Letters · 被引 68)